SIGY — Sigyn Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $7.76m
- $9.96m
Annual cashflow statement for Sigyn Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -3.07 | -1.26 | -3 | -2.93 | -4.15 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 2.51 | 0.343 | 1.21 | 0.782 | 2.26 |
| Discontinued Operations | |||||
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.349 | 0.075 | -0.003 | 0.307 | 0.497 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -0.144 | -0.83 | -1.77 | -1.83 | -1.38 |
| Capital Expenditures | 0 | — | -0.029 | -0.001 | — |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 0.1 | -0.011 | 0 | — | — |
| Sale of Business | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 0.1 | -0.011 | -0.029 | -0.001 | — |
| Financing Cash Flow Items | — | — | — | -0.069 | 0.075 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 0.037 | 0.925 | 2.06 | 1.5 | 1.39 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -0.007 | 0.084 | 0.257 | -0.333 | 0.003 |